February 20, 2019 10:31 AM EST
News Briefing

Kalei­do sets terms for $100M IPO; Mallinck­rodt touts pos­i­tive PhI­II GVHD da­ta, cuts tri­al short

Natalie Grover

Reporter

→ Mi­cro­bio­me drug de­vel­op­er Kalei­do Bio­sciences set the terms for its IPO on Tues­day, fol­low­ing in the foot­steps of Gos­samer Bio, Har­poon Ther­a­peu­tics and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

A service from the Financial Times